ANTIBODY-TARGETED THROMBOLYTIC AGENTS : The 53th Annual Scientific Session of the Japanese Circulation Society

スポンサーリンク

概要

• 論文の詳細を見る

• Plasminogen activator therapy for acute myocardial infarction has become standard medical practice. Bleeding complications, however, limit the utility of the currently available agents. This article reviews how the tools of immunology, molecular biology and protein engineering are being used to develop safer and more effective plasminogen activators.

• 社団法人日本循環器学会の論文
• 1990-04-20

著者

• Quertermous Thomas

  Cardiac Unit Massachusetts General Hospital Boston

• Runge Marshall

  Cardiac Unit Massachusetts General Hospital Boston

• HABER EDGAR

  President, The Squibb Institute for Medical Research, Princeton

• MATSUEDA GARY

  Cardiac Unit, Massachusetts General Hospital, Boston

• BODE CHRISTOPH

  Medizinische Klinik III (Kardiologie) der Universitat Heidelberg

• Haber Edgar

  President The Squibb Institute For Medical Research Princeton

• Matsueda Gary

  Cardiac Unit Massachusetts General Hospital Boston

関連論文

• ANTIBODY-TARGETED THROMBOLYTIC AGENTS : The 53th Annual Scientific Session of the Japanese Circulation Society

スポンサーリンク